drugset / Trial / NCT02033018

Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization

NCT02033018

Phase 4 Unknown 20 enrolled Instituto de Olhos de Goiania
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary

Timeline

Start
2013-10
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 0.5 mg Intravitreal